Its approval in this new indication should help increase the medicine's strong performance, and it's pursuing several other label expansions. Eli Lilly can also count on many years of sales growth ...

Financial writer cautious on Eli Lilly stock despite strong performance, citing high valuation and underperforming drugs.

Eli Lilly's diverse product portfolio and promising pipeline, including Tirzepatide, Orforglipron, and Retatrutide ... Semaglutide and potential to obtain label expansions associated with obesity ...

This top healthcare company trades at 13 times forward earnings. It has a diverse portfolio of products, yields 3.6% at the ...

First, tirzepatide, which it markets as Zepbound and Mounjaro, could earn label ... Eli Lilly's work in the weight loss area looks particularly exciting. Its late-stage pipeline features ...

Eli Lilly LLY and Novo Nordisk ... respectively. Lilly and Novo Nordisk also market their diabetes drugs, Mounjaro and Ozempic, off-label for weight loss. Oral pills like HS-10535, if approved ...

Eli Lilly and Company’s LLY shares declined 13.5% in the past three months. Though demand for its popular tirzepatide drugs, ...